EU governments ban malaria drug for COVID-19, trial paused as safety fears grow

European governments moved, on Wednesday, to halt the use of anti-malaria drug hydroxychloroquine to treat COVID-19 patients, and a second global trial was suspended, further blows to hopes for a treatment promoted by US President Donald Trump.

The moves by France, Italy and Belgium followed a World Health Organisation decision on Monday to pause a large trial of hydroxychloroquine due to safety concerns.

A UK regulator said on Wednesday that a separate trial was also being put on hold, less than a week after it started. The study, being led by the University of Oxford and partly funded by the Bill and Melinda Gates Foundation, was expected to involve as many as 40,000 healthcare workers.

“All hydroxychloroquine trials in COVID-19 remain under close review” while investigators assess any further risks, the Medicines and Healthcare products Regulatory Agency (MHRA) said in an email to Reuters.

The swift moves by authorities in countries hit hardest by the pandemic highlighted the challenge for governments scrambling to find ways to treat patients and control the novel coronavirus.

After early reports that it might help some patients, regulators in several countries had allowed hydroxychloroquine to be used as a potential COVID-19 treatment.

Trump was a particularly strong supporter, describing the drug as a “gamechanger.” He later announced he was taking it to prevent infection.

However, more recent studies have raised serious safety issues. British medical journal The Lancet has reported coronavirus patients receiving hydroxychloroquine were more likely to die and experience dangerous irregular heartbeats.

On Wednesday, France’s health ministry cancelled a decree in place for nearly two months that had allowed hospital doctors to dispense it in specific situations for COVID-19.

Medicines agencies in France and Italy said the drug should not be used for COVID-19 outside clinical trials. Belgium’s regulator said trials aiming to evaluate the drug should also take potential risks into consideration.

Swiss drugmaker Novartis (NOVN.S) is pushing ahead with its U.S. study involving 440 patients, while French company Sanofi (SASY.PA) declined to comment on the future of its two trials.

Italian health authorities concluded that the risks, coupled with little evidence hydroxychloroquine was beneficial against COVID-19, merited a ban outside of clinical trials.

“New clinical evidence on the use of hydroxychloroquine in subjects with SARS-CoV-2 infection … indicates an increased risk for adverse reactions with little or no benefit,” medicines agency AIFA said.

The WHO said a safety panel would evaluate by mid-June the drug’s use in its multi-country trial of potential COVID-19 treatments.

Germany is looking at The Lancet study and the WHO’s decision but has not made any decision about new guidance on hydroxychloroquine, a spokeswoman for its drugs regulator said.

The US Food and Drug Administration has allowed healthcare providers to use hydroxychloroquine for COVID-19 through an emergency-use authorisation, but has not approved them to treat it. It also warned in April, that for safety reasons, the drug should be used only for hospitalised COVID-19 patients or those in clinical trials.

The agency did not respond to queries asking whether it was reconsidering the emergency-use authorisation.

(Reuters)

YOU SHOULD NOT MISS THESE HEADLINES FROM NIGERIAN TRIBUNE

Buy and read digital replicas of your TRIBUNE titles by subscribing through E-VENDING

Pantami Used Armed Officers To Evict Our Staff, Abike Dabiri Alleges
The chairman, Nigerians in the Diaspora Commission (NIDCOM), Abike Dabiri-Erewa, has alleged that the Minister of Communications and Digital Economy, Dr Isa Pantami used armed security men to eject NIDCOM from the offices which they occupied in the NCC building located at Mbora District… Read full story

Naira Set To Rally As CBN, ABCON Finalise BDCs’ Resumption Of Forex Sale
The naira is facing its greatest risk from the COVID-19 pandemic as currency speculators continue to make spurious demand for dollar with the hope of making good returns from the rising gaps between… Read full story

MONDAY LINE: Buhari’s Fifth May 29
MUHAMMADU Buhari’s first coming was from December 31, 1983 to August 27, 1985. It was a period of famine and pestilence; of queues for coins and corn and of lean liberty. His second coming will be five years old on Friday. Can he sit back and use his tongue to count his teeth? What has changed between his past… Read full story

China Tells US To Stop Wasting Time In Coronavirus Battle
The US should stop wasting time in its fight against the coronavirus and work with China to combat it, rather than spreading lies and attacking the country, the Chinese Government’s top diplomat, Wang Yi, said on Sunday. The Sino-US ties have nosedived since the outbreak of the new coronavirus… Read full story

The Continued Harassment Of Essential Workers
NOT a few Nigerians were miffed by the reports of arbitrary arrests and continued harassment of essential workers by the police immediately after the recent extension by the Federal Government of the partial lockdown and curfew imposed across the country to curtail the spread of the Covid-19 global pandemic. Initially,many thought that the police operatives were at it again, acting outside their briefs for pecuniary gain… Read full story

Subsidy Removal: Those Who Can’t Fix Refineries Should Give Way ― NLC
The Nigeria Labour Congress (NLC) has warned that the Federal Government should not talk about; or contemplate fuel price increase; even as it stated that subsidy is a cover-up for inefficiency and corrupt in the system. The NLC gave this position, as the Petroleum and Natural Gas Senior Staff Association… Read full story